uniQure (NASDAQ:QURE) Sets New 52-Week High – Time to Buy?

Shares of uniQure (NASDAQ:QURE) hit a new 52-week high during trading on Monday . The stock traded as high as $17.95 and last traded at $17.71, with a volume of 450937 shares changing hands. The stock had previously closed at $16.98.

Wall Street Analyst Weigh In

QURE has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Mizuho lifted their price target on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, Cantor Fitzgerald upped their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.88.

uniQure Stock Down 0.5 %

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50-day simple moving average of $8.36 and a 200-day simple moving average of $6.86. The firm has a market capitalization of $845.69 million, a PE ratio of -3.50 and a beta of 0.89.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Analysts forecast that uniQure will post -3.82 EPS for the current year.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. bought a new stake in shares of uniQure during the third quarter valued at about $7,360,000. Geode Capital Management LLC increased its holdings in uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after acquiring an additional 6,362 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in uniQure during the 3rd quarter worth approximately $283,000. Quarry LP purchased a new stake in uniQure in the 3rd quarter worth approximately $58,000. Finally, RTW Investments LP bought a new position in uniQure in the 3rd quarter valued at $49,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.